Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
AIM: IMpower133 was designed with 4 cycles of chemoimmunotherapy with atezolizumab, unlike many other studies permitted 6-cycle induction. This study aimed to compare the efficacy and safety of a 4-cycle regimen with an extended 6-cycle regimen of carboplatin, etoposide, and atezolizumab in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). METHODS: This retrospective multicenter study was conducted across 13 oncology centers in Turkey. A total of 181 patients with ES-SCLC who received first-line treatment with chemotherapy plus atezolizumab were analyzed and grouped into those receiving 4 cycles (n = 101) and 6 cycles (n = 80) of treatment. RESULTS: The median follow-up time was 20.9 months. The objective response rates were similar between the 4- and 6-cycle groups (79.2% vs 78.8%, P = .940). The disease control rates were also comparable (84.2% vs 86.3%, P = .940). The median progression-free survival (PFS) was 6.3 months in the 4-cycle and 8.1 months in the 6-cycle group (P = .357). The median overall survival (OS) was 16.6 months for the 4-cycle and 13.6 months for the 6-cycle group (P = .583). Intracranial progression was higher in the 4-cycle group (50.0% vs 25.5%, P = .007). Immune-related adverse events were similar between the groups. CONCLUSION: This is one of the largest real-world datasets comparing the efficacy and safety of 4 versus 6 cycles of induction chemoimmunotherapy. Although there were no significant improvements in PFS or OS, the 6-cycle regimen was associated with a lower observed rate of intracranial progression, predominantly among patients without baseline brain metastases. Further studies are needed to identify this subject in future.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis
- Date Crossref
- 09/03/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Antalya Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Memorial Ankara Hospital pays non établi dans la noticeÉtablissement de santé
-
Liv Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Samsun University pays non établi dans la noticeUniversité ou école supérieure
-
Ordu University pays non établi dans la noticeUniversité ou école supérieure
-
Gülhane Askerî Tıp Akademisi pays non établi dans la noticeÉtablissement de santé
-
Bursa Uludağ Üni̇versi̇tesi̇ pays non établi dans la noticeUniversité ou école supérieure
-
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Bilkent University pays non établi dans la noticeUniversité ou école supérieure
-
Hacettepe University Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Ankara Atatürk Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Mersin Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
Antalya Eğitim ve Araştırma Hastanesi, Memorial Ankara Hospital et Department of Medical Oncology — Liv Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.